🎧 Prefer to listen?
Anthropic just announced it’s going to develop its own drugs. Not partner with pharma companies. Not license Claude to labs. Actually discover and develop treatments — starting with what it calls “neglected” diseases. If you’re a solo builder using Claude to run your business, this sounds like a headline from a different universe. But I think there’s something here that directly affects how you should be thinking about your tools.
What actually happened
At their “The Briefing: AI for Science” event, Anthropic launched two things. First, Claude Science — a dedicated workbench that pulls fragmented research tools, datasets, and visualization into one environment. Second, a commitment to use that workbench internally to discover drug candidates.
This puts Anthropic in a strange position. They’re selling Claude to pharma companies like AstraZeneca, Novo Nordisk, and GSK — and simultaneously competing with those same customers by developing drugs themselves. As The Verge reported, experts called AI drug discovery a “catchall phrase” that applies to every stage of the process, from finding new compounds to supporting clinical trials. Anthropic isn’t just building tools for that process — they’re jumping into it.
The details are sparse. They haven’t said which diseases they’ll target first, whether they’ll partner with existing drug companies for lab work and trials, or what happens if they actually find a promising candidate. What they have said is that generative AI can search across vast chemical and biological possibilities and suggest connections that would take humans years to find.
Why this matters beyond pharma
Here’s the thing that jumped out at me: Claude Science is essentially what Cowork does, but for scientific research. It’s a unified environment where you point the AI at your domain, give it access to your tools and data, and let it work.
I covered this pattern when Anthropic launched Cowork — the three-layer approach where Claude handles local files, connects to external services, and interacts with the browser. Claude Science applies that same architecture to a specific vertical. The underlying principle is identical: consolidate fragmented workflows into a single AI-powered environment.
If you’re building a solo business, this pattern is the takeaway. Not “should I use Claude for drug discovery” — but “what would a Claude-powered workbench look like for my workflow?”
The consolidation pattern you can steal
Think about what Claude Science actually does for researchers:
- Replaces tab-switching. Instead of jumping between databases, visualization tools, spreadsheets, and papers — everything lives in one environment.
- Connects data sources. It pulls from fragmented datasets and finds patterns across them.
- Generates outputs. Figures, visuals, summaries — produced directly from the research context.
Now map that to a solo builder’s typical day. You’re jumping between Notion for planning, your email for client communication, a spreadsheet for finances, and three different AI tools for content creation. What if Claude could sit in the middle of all of that?
With Cowork, you can already point Claude at a folder and have it read, organize, and create files. With Claude’s connectors, it can pull data from services like Asana and Notion. The pieces exist — they’re just not packaged as neatly as Claude Science.
What Anthropic’s strategy tells us about AI’s direction
There’s a bigger signal here. Anthropic isn’t positioning Claude as a general-purpose chatbot anymore. They’re building vertical-specific workbenches — first coding with Claude Code, then general productivity with Cowork, now science with Claude Science.
This is the same trajectory I wrote about when comparing the AI agent landscape — the shift from “ask the AI a question” to “give the AI a job.” Each workbench is a more complete version of that idea: a dedicated environment where the AI doesn’t just answer questions but executes workflows.
For solo builders, the implication is clear: the tools you’re using today are going to get significantly more integrated. The question isn’t whether Claude can handle your workflow — it’s whether you’re ready to hand it the keys.
The risk nobody’s talking about
Anthropic selling Claude to pharma companies while developing its own drugs creates a conflict of interest that the industry hasn’t fully grappled with. If you’re AstraZeneca and you learn your AI tool provider is now competing with you in drug discovery, do you keep using Claude?
This is relevant for solo builders too. When a platform you depend on starts competing in your space — the same concern that came up when Asana acquired StackAI — you need a plan. The smart move is to stay tool-agnostic. Use Claude, but don’t build everything exclusively on Claude. I covered this philosophy in the tools I actually use every day — diversification isn’t just about features, it’s about risk.
What to do with this information
You don’t need to start a drug company. But you should watch the Claude Science pattern closely, because it’s coming to every vertical. Here’s what I’d do today:
If you use Claude for business: Start experimenting with Cowork on a real project. Point it at your client files, your content calendar, your financial documents. See how far the three-layer approach gets you before Claude Science-level tools arrive for your domain.
If you’re evaluating AI tools: Add “vertical workbench” to your criteria. The next wave of AI products won’t be general-purpose — they’ll be domain-specific environments. Cursor already does this for coding. Claude Science does it for research. Your industry is next.
If you’re building something: Think about what a “workbench” version of your product would look like. The pattern — consolidate tools, connect data sources, generate outputs — applies to almost every service business. If Anthropic thinks this pattern is worth investing billions in drug development, it’s probably worth considering for your solo operation.
The bottom line
Anthropic entering drug development isn’t just a pharma story. It’s a signal that AI is moving from general-purpose assistants to domain-specific workbenches — and the consolidation pattern they’re using applies to every solo builder’s workflow. Start experimenting with what exists today, because the next generation of tools is going to look a lot more like Claude Science than a chatbot.
If you’re new to building with AI tools, start here — I cover the fundamentals of setting up your first AI-powered workflow from scratch.